Open AccessLanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients
Author(s) -
Emilio GonzálezParra,
María Luisa GonzálezCasaus,
A Galán,
Alberto Martinez-Calero,
Víctor Navas,
Mariano Rodriguez,
Alberto Ortíz
Publication year - 2011
Publication title -
nephrology, dialysis, transplantation/nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfr144
Subject(s) - lanthanum carbonate , fibroblast growth factor 23 , medicine , phosphate binder , phosphate , endocrinology , kidney disease , sevelamer , parathyroid hormone , excretion , interquartile range , urinary system , hypophosphatemia , chemistry , calcium , hyperphosphatemia , biochemistry
In chronic kidney disease (CKD) patients, the ability to excrete a phosphate load is impaired. Compensatory increase in parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) promote phosphaturia. Serum FGF23 concentration is considered an early biomarker of excess phosphate load and high levels of FGF23 have been associated with increased mortality. In the present study, we have evaluated the changes in plasma FGF23 after treatment with the phosphate binder lanthanum carbonate in patients with CKD-3 and a normal serum phosphate concentration.